Summary
Introduction Genexol-PM is a novel Cremophor® EL (CrEL)-free polymeric micelle formulation of paclitaxel. This multicenter phase II study was designed to evaluate the efficacy and safety of Genexol-PM monotherapy in patients with advanced urothelial carcinoma who developed disease progression after gemcitabine and cisplatin combination chemotherapy. Patients and Methods Patients received Genexol-PM 240 mg/m2 intravenously over 3 h every 3 weeks without premedication. Intra-patient dose escalation to 300 mg/m2 was allowed during the second and subsequent cycles if pre-specified toxicities were not observed during the first cycle. The primary endpoint was response. Results Thirty-seven patients were enrolled in this study. Platinum-free interval was less than 6 months in 27 (73%) patients, and 24 (64%) were categorized as having intermediate or poor prognosis according to Bajorin’s criteria. Of 34 evaluable patients, there were 7 responses (21%; 95% CI, 7–34%), including one complete response (CR), with a median response duration of 6.5 months (95% CI, 3.5–9.6 months). The median time to progression was 2.7 months (95% CI, 0.9–4.6 months) with a median overall survival of 6.5 months (95% CI, 5.0–8.0 months). The most common grade 3/4 non-hematologic toxicities were peripheral neuropathy (sensory type 5.9%; motor type 8.8%) and infection (5.9%). Grade ≥3 hematologic toxicities occurred in only one patient. Conclusion Genexol-PM was generally well tolerated and demonstrated sufficient antitumor activity to warrant further development when used as second-line chemotherapy after gemcitabine-cisplatin failure in patients with urothelial carcinoma (NCT01426126).
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077
Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Collette L (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42(1):50–54. doi:10.1016/j.ejca.2005.08.032
Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study [published erratum appears in J Clin Oncol 1993 Feb;11(2):384]. J Clin Oncol 10(7):1066–1073
Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6):1050–1055
von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. J Clin Oncol 23(21):4602–4608. doi:10.1200/jco.2005.07.757
Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS (2007) Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69(1 Suppl):62–79. doi:10.1016/j.urology.2006.10.041
Bajorin DF (2000) Paclitaxel in the treatment of advanced urothelial cancer. Oncology (Williston Park) 14(1):43–52, 57; discussion 58, 61–42
Raghavan D (2003) Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer 97(8 Suppl):2050–2055. doi:10.1002/cncr.11280
Joly F, Houédé N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, Rolland F, Fléchon A, Henry-Amar M, Culine S (2009) Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer 7(2):E28–E33
Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J (1997) Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 75(4):606–607
Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB (2002) Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20(4):937–940
Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590–1598
Kintzel PE (2001) Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 35(9):1114–1117
Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90(2):304–305
Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N et al (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12(12):2654–2666
Ganning AE, Brunk U, Dallner G (1984) Phthalate esters and their effect on the liver. Hepatology 4(3):541–547
Waugh WN, Trissel LA, Stella VJ (1991) Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 48(7):1520–1524
van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A (2001) Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47(4):309–318
Kim T-Y, Kim D-W, Chung J-Y, Shin SG, Kim S-C, Heo DS, Kim NK, Bang Y-J (2004) Phase I and pharmacokinetic study of genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10(11):3708–3716
Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH (2001) In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 72(1–3):191–202. doi:10.1016/s0168-3659(01)00275-9
Kim SC, Yoon HJ, Lee JW, Yu J, Park ES, Chi SC (2005) Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles. Int J Pharm 293(1–2):303–310. doi:10.1016/j.ijpharm.2005.01.011
Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, Park K, Lee MY, Heo DS (2007) Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 18(12):2009–2014. doi:10.1093/annonc/mdm374
Lee K, Chung H, Im S, Park Y, Kim C, Kim S-B, Rha S, Lee M, Ro J (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108(2):241–250. doi:10.1007/s10549-007-9591-y
Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11(9):861–870. doi:10.1016/S1470-2045(10)70086-3
McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15(5):1853–1857
Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F (1997) Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 20(5):519–521
Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, Pj Loehrer Sr (1997) Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15(2):589–593
Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27(27):4454–4461. doi:10.1200/JCO.2008.20.5534
Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V, George C (2009) Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 115(18):4110–4117. doi:10.1002/cncr.24460
Sridhar SS, Canil CM, Mukherjee D, Winquist E, Elser C, Eisen A, Reaume N, Zhang L, Ko YJ (2011) A phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma. J Clin Oncol (Meeting Abstracts) 29 (suppl 7):abstr 241
Mielke S, Sparreboom A, Mross K (2006) Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 42(1):24–30. doi:10.1016/j.ejca.2005.06.030
Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17(10):3173–3181
Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850–1855. doi:10.1200/JCO.2009.25.4599
Acknowledgments
Genexol-PM was provided by Samyang Co. Seoul, Korea. This study was presented in part at the 2011 ASCO Genitourinary Cancer Symposium, Orlando, FL, USA, February 17–19, 2011.
Financial disclosure and Conflicts of interest
Nothing special to be declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, JL., Ahn, JH., Park, S.H. et al. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs 30, 1984–1990 (2012). https://doi.org/10.1007/s10637-011-9757-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-011-9757-7